Ken Beckman, MD, FACS, is a corneal specialist and clinical assistant professor at The Ohio State University. At the 2025 ...
After Christmas dinner in 2021, our family was glued to the television, watching the nail-biting launch of NASA's US$10 ...
In the Phase 2 TEASE 2 trial, gildeuretinol was well tolerated and showed promising trends in slowing ellipsoid zone loss and preserving low-luminance visual acuity in patients with Stargardt disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback